Abdominal wall blocks in robotic hysterectomy for endometrial cancer are associated with a modest reduction in the frequency of patients receiving post-operative intravenous opioids

在机器人辅助子宫切除术治疗子宫内膜癌时,腹壁阻滞可略微降低患者术后接受静脉注射阿片类药物的频率。

阅读:1

Abstract

OBJECTIVE: To evaluate the association of abdominal wall blocks at the time of robotic hysterectomy performed for endometrial cancer (EC) with in-hospital post-operative opioids. METHODS: We performed a retrospective cohort study of patients in the Vizient database who had robotic hysterectomy for EC between January 2019 and December 2022. The exposure was any block coded separate from the surgery, and the primary outcomes were any IV/oral opioid. Fentanyl was excluded due to frequent intra-op use. Length of stay (LOS) and direct cost were compared. The association between block and opioid use was assessed via risk ratio. The quantity of each opioid was expressed in standard resource units (SRU) - a metric used to standardize the consumption of medications across facilities. RESULTS: Three hundred and twenty of the 9062 patients (3.5 %) had a block and 8,742 (96.5 %) did not. Blocks were performed at 66 (20.4 %) hospitals. 184 patients (57.5 %) in the block group received an IV opioid vs 5,890 (67.4 %) of the patients without a block (RR 0.85, 95 % CI 0.77-0.94, p < 0.001). Patients who received blocks were less likely to receive IV (52.5 % vs 64.8 %, RR 0.81, 95 % CI 0.73-0.89, p < 0.001) and oral hydromorphone (6.9 % vs 3.9 %, RR 2.53, 95 % CI 1.68-3.81, p < 0.001) and more likely to receive oral hydrocodone/acetaminophen (11.3 % vs 0.88 %, RR 12.77, 95 % CI 8.73-18.67, p < 0.001). CONCLUSION: Blocks are infrequently performed and are associated with a modest reduction in the number of patients receiving post-op IV opioids. We found no difference in LOS or cost. Limitations include lack of detail regarding type of block, anesthetic, and phase of care.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。